Paola Fazi
A5016635620- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Retinoids in leukemia and cellular processes
- Histone Deacetylase Inhibitors Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Cancer survivorship and care
- Eosinophilic Disorders and Syndromes
- Platelet Disorders and Treatments
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- HIV/AIDS drug development and treatment
- Pharmacological Effects and Toxicity Studies
- Hematological disorders and diagnostics
- Neutropenia and Cancer Infections
- Drug-Induced Ocular Toxicity
- Antioxidant Activity and Oxidative Stress
- Blood groups and transfusion
- CAR-T cell therapy research
Fondazione Gimema Onlus
2016-2025
Center for Outcomes Research and Clinical Epidemiology
2019-2024
Mandelli (Italy)
2019-2023
National Tsunami Warning Center
2021
Sapienza University of Rome
2000-2019
International Flame Research Foundation
2010-2019
Gilead Sciences (United States)
2016
Klinikum Bremen-Mitte
2016
University Medical Center Hamburg-Eppendorf
2016
Universität Hamburg
2016
Nucleophosmin (NPM), a nucleocytoplasmic shuttling protein with prominent nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations involving NPM gene cause cytoplasmic dislocation of protein.We used immunohistochemical methods to study subcellular localization in bone marrow-biopsy specimens from 591 patients primary acute myelogenous leukemia (AML). We then correlated presence clinical and biologic features disease.Cytoplasmic was detected 208 (35.2 percent)...
All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies treatment arsenic trioxide or without ATRA have shown high efficacy and reduced hematologic toxicity.We conducted a phase 3, multicenter trial comparing plus patients APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either induction consolidation...
Purpose The initial results of the APL0406 trial showed that combination all- trans-retinoic acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA chemotherapy (CHT) in first-line therapy low- or intermediate-risk acute promyelocytic leukemia (APL). We herein report final analysis on complete series patients enrolled onto this trial. Patients Methods study was a prospective, randomized, multicenter, open-label, phase III noninferiority Eligible were adults between...
To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care (BSC) including hydroxyurea as first-line therapy in older patients acute myeloid leukemia unsuitable for intensive chemotherapy.In this trial, at least 61 years old were centrally randomized (1:1) to receive either a single induction course of GO (6 mg/m(2) on day 1 and 3 8) or BSC. Patients who did not progress after could up eight monthly infusions the immunoconjugate 2 mg/m(2). Randomization was stratified by...
Purpose The causes of the aggressive nature BCR-ABL1–positive adult acute lymphoblastic leukemia (ALL) are unknown. To identify, at submicroscopic level, oncogenic lesions that cooperate with BCR-ABL1 to induce ALL, we performed an investigation genomic copy number alterations using single nucleotide polymorphism array, polymerase chain reaction, and sequencing candidate genes. Patients Methods Eighty-three patients de novo Philadelphia chromosome (Ph) –positive ALL were enrolled onto...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned coprimary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. We report long-term of frontline with dasatinib and blinatumomab induction/consolidation (GIMEMA LAL2116, D-ALBA)...
Purpose To compare the antitumor efficacy of three different anthracyclines in combination with cytarabine and etoposide adult patients newly diagnosed acute myeloid leukemia (AML). Patients Methods We randomly assigned 2,157 (age range, 15 to 60 years) receive intensive induction-consolidation chemotherapy containing either daunorubicin, idarubicin, or mitoxantrone. After achieving complete remission (CR), were undergo allogeneic autologous stem-cell transplantation (SCT), depending on...
Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days cytarabine at daily dose 100 200 mg/m(2) for remission induction. Consensus has not been reached on benefit higher dosages cytarabine.The European Organisation Research and Treatment Cancer (EORTC) Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Leukemia Groups conducted randomized trial (AML-12; Combination Chemotherapy, Stem Cell Transplant Interleukin-2...
The outcome of children and adults with acute lymphoblastic leukemia is markedly different. Since there limited information on the distribution clinico-biological variables in different age cohorts, we analyzed 5202 patients enrolled Italian multicenter AIEOP GIMEMA protocols stratified them nine cohorts. highest prevalence was observed children, although a second peak recorded from 4th decade onwards. Interestingly, lowest incidence found females between 14–40 years. Immunophenotypic...
Abstract Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival CML patients has become very close to normal. The next, ambitious, step is bring as many possible into a condition treatment-free remission (TFR). Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA; Italian Group for Hematologic Diseases Adult) Working Party (WP) developed project aimed at...
<h3>Importance</h3> Convalescent plasma (CP) has been generally unsuccessful in preventing worsening of respiratory failure or death hospitalized patients with COVID-19 pneumonia. <h3>Objective</h3> To evaluate the efficacy CP plus standard therapy (ST) vs ST alone <h3>Design, Setting, and Participants</h3> This prospective, open-label, randomized clinical trial enrolled (1:1 ratio) pneumonia to receive between July 15 December 8, 2020, at 27 sites Italy. Hospitalized adults a partial...
PURPOSE: Recent reports of extramedullary disease (EMD) at recurrence in acute promyelocytic leukemia (APL) have raised increasing concern about a possible role retinoic acid (RA) therapy. PATIENTS AND METHODS: We analyzed the risk developing EMD localization relapse APL patients enrolled onto two consecutive studies Gruppo Italiano Malattie Ematologiche dell’Adulto. The investigated chemotherapy alone (LAP0389) versus RA plus (AIDA). RESULTS: When all types were taken into account, 94 (51%)...